$PCRX
Pacira Biosciences Inc Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000139681421000063 Filed on November 03, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$159.2M	$127.7M	$117.5M
YoY Change	21.55%	8.71%	12.23%
Cost Of Revenue	$39.01M	$34.65M	$29.99M
YoY Change	10.51%	15.53%	34.47%
Gross Profit	$120.2M	$93.07M	$87.49M
YoY Change	25.62%	6.38%	6.2%
Gross Profit Margin	75.5%	72.87%	74.47%
Selling, General & Admin	$51.20M	$48.81M	$52.56M
YoY Change	-3.02%	-7.14%	4.85%
% of Gross Profit	42.6%	52.44%	60.08%
Research & Development	$15.51M	$11.58M	$14.65M
YoY Change	1.4%	-20.97%	-27.67%
% of Gross Profit	12.91%	12.44%	16.75%
Depreciation & Amortization	$13.07M	$3.800M	$3.100M
YoY Change	158.3%	22.58%	-13.89%
% of Gross Profit	10.87%	4.08%	3.54%
Operating Expenses	$74.37M	$60.39M	$67.21M
YoY Change	6.09%	-10.16%	-34.28%
Operating Profit	$45.82M	$31.43M	$17.62M
YoY Change	79.14%	78.39%	630.21%
Interest Expense	-$10.34M	$7.333M	$7.132M
YoY Change	61.61%	2.82%	20.07%
% of Operating Profit	-22.57%	23.33%	40.48%
Other Income/Expense, Net	-$66.00K	-$7.202M	-$11.47M
YoY Change	-122.0%	-37.21%	39.39%
Pretax Income	-$6.198M	$24.23M	$6.150M
YoY Change	-148.8%	294.0%	-205.74%
Income Tax	-$1.068M	$6.600M	-$124.0M
% Of Pretax Income		27.24%	-2016.26%
Net Earnings	-$5.130M	$17.66M	$130.1M
YoY Change	-135.35%	-86.43%	-2237.65%
Net Earnings / Revenue	-3.22%	13.83%	110.75%
Basic Earnings Per Share		$0.40	$3.03
Diluted Earnings Per Share	-$115.0K	$0.39	$2.94
COMMON SHARES
Basic Shares Outstanding	44.54M shares	44.48M shares	42.93M shares
Diluted Shares Outstanding		45.46M shares	44.28M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$656.4M	$693.9M	$532.1M
YoY Change	25.82%	30.4%	100.34%
Cash & Equivalents	$585.6M	$134.0M	$125.2M
Short-Term Investments	$70.83M	$559.8M	$406.9M
Other Short-Term Assets	$14.77M	$11.31M	$11.70M
YoY Change	20.09%	-3.33%	12.5%
Inventory	$98.55M	$67.21M	$68.54M
Prepaid Expenses
Receivables	$96.32M	$49.98M	$46.14M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$866.0M	$822.4M	$658.5M
YoY Change	32.91%	24.88%	73.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$188.4M	$159.2M	$125.5M
YoY Change	37.83%	26.85%	19.71%
Goodwill	$145.2M	$99.50M	$99.50M
YoY Change	45.86%	0.0%	-0.05%
Intangibles	$624.0M	$90.62M	$98.49M
YoY Change	546.46%	-7.99%	-7.4%
Long-Term Investments	$21.99M	$21.19M	$12.80M
YoY Change	-79.92%	65.56%	-84.41%
Other Assets	$153.4M	$93.27M	$104.1M
YoY Change	44.41%	-10.41%
Total Long-Term Assets	$1.209B	$533.7M	$561.7M
YoY Change	94.14%	-5.0%	31.05%
TOTAL ASSETS
Total Short-Term Assets	$866.0M	$822.4M	$658.5M
Total Long-Term Assets	$1.209B	$533.7M	$561.7M
Total Assets	$2.075B	$1.356B	$1.220B
YoY Change	62.83%	11.12%	51.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.54M	$7.895M	$13.01M
YoY Change	1.07%	-39.31%	-19.02%
Accrued Expenses	$127.6M	$50.80M	$60.40M
YoY Change	79.72%	-15.9%	-0.98%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due	$374.7M	$155.8M
YoY Change	150.47%
Total Short-Term Liabilities	$521.1M	$225.8M	$86.27M
YoY Change	105.71%	161.72%	-9.98%
LONG-TERM LIABILITIES
Long-Term Debt	$674.5M	$326.1M	$456.5M
YoY Change	115.5%	-28.56%	51.11%
Other Long-Term Liabilities	$19.97M	$7.553M	$4.219M
YoY Change	421.19%	79.02%	81.85%
Total Long-Term Liabilities	$19.97M	$7.553M	$4.219M
YoY Change	421.19%	79.02%	81.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$521.1M	$225.8M	$86.27M
Total Long-Term Liabilities	$19.97M	$7.553M	$4.219M
Total Liabilities	$1.345B	$637.4M	$635.6M
YoY Change	105.39%	0.29%	37.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$211.9M	-$206.8M	-$268.4M
YoY Change	-16.54%	-22.96%	-31.97%
Common Stock	$45.00K	$45.00K	$43.00K
YoY Change	2.27%	4.65%	2.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$730.4M	$718.6M	$584.7M
YoY Change
Total Liabilities & Shareholders Equity	$2.075B	$1.356B	$1.220B
YoY Change	62.83%	11.12%	51.12%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$5.130M	$17.66M	$130.1M
YoY Change	-135.35%	-86.43%	-2237.65%
Depreciation, Depletion And Amortization	$13.07M	$3.800M	$3.100M
YoY Change	158.3%	22.58%	-13.89%
Cash From Operating Activities	$23.22M	$60.29M	$39.79M
YoY Change	-50.25%	51.51%	116.72%
INVESTING ACTIVITIES
Capital Expenditures	-$9.166M	-$13.08M	-$7.760M
YoY Change	-36.39%	68.51%	388.05%
Acquisitions
YoY Change
Other Investing Activities	$76.08M	-$22.00M	-$195.1M
YoY Change	-212.04%	-88.72%	-2802.08%
Cash From Investing Activities	$66.92M	-$35.08M	-$202.9M
YoY Change	-181.29%	-82.71%	-3703.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	361.4M	3.052M	209.8M
YoY Change	3388.5%	-98.55%	14671.83%
NET CHANGE
Cash From Operating Activities	23.22M	60.29M	39.79M
Cash From Investing Activities	66.92M	-35.08M	-202.9M
Cash From Financing Activities	361.4M	3.052M	209.8M
Net Change In Cash	451.5M	28.26M	46.70M
YoY Change	-1884.75%	-39.48%	83.79%
FREE CASH FLOW
Cash From Operating Activities	$23.22M	$60.29M	$39.79M
Capital Expenditures	-$9.166M	-$13.08M	-$7.760M
Free Cash Flow	$32.38M	$73.36M	$47.55M
YoY Change	-46.98%	54.29%	138.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35060
	dei	Entity Registrant Name EntityRegistrantName	PACIRA BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	51-0619477
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5401 West Kennedy Boulevard, Suite 890
	dei	Entity Address City Or Town EntityAddressCityOrTown	Tampa
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33609
	dei	City Area Code CityAreaCode	813
	dei	Local Phone Number LocalPhoneNumber	553-6680
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Trading Symbol TradingSymbol	PCRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44544489	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134036000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99957000	USD
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	559822000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	421705000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	49975000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53046000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	67209000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	64650000	USD
CY2021Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	395000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	114000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11310000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12265000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	822352000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	651623000	USD
CY2021Q3	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	95459000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	159235000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	136688000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	69790000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	74492000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	99547000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	99547000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	90621000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	96521000	USD
CY2021Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	93265000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	106164000	USD
CY2021Q3	pcrx	Equity Method Investments And Other Assets EquityMethodInvestmentsAndOtherAssets	21192000	USD
CY2020Q4	pcrx	Equity Method Investments And Other Assets EquityMethodInvestmentsAndOtherAssets	14019000	USD
CY2021Q3	us-gaap	Assets Assets	1356002000	USD
CY2020Q4	us-gaap	Assets Assets	1274513000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7895000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10431000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50798000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	70974000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5879000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7425000	USD
CY2021Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	155751000	USD
CY2021Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	155751000	USD
CY2020Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	149648000	USD
CY2020Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	149648000	USD
CY2021Q3	pcrx	Contingent Consideration Current ContingentConsiderationCurrent	5070000	USD
CY2020Q4	pcrx	Contingent Consideration Current ContingentConsiderationCurrent	14736000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	225788000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	253328000	USD
CY2021Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	326146000	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	313030000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	66784000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71025000	USD
CY2021Q3	pcrx	Contingent Consideration Noncurrent ContingentConsiderationNoncurrent	11129000	USD
CY2020Q4	pcrx	Contingent Consideration Noncurrent ContingentConsiderationNoncurrent	13610000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7553000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3832000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	637400000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	654825000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44523410	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44523410	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43636929	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43636929	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	45000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	44000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	925169000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	873201000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-206765000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253875000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	153000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	318000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	718602000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	619688000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1356002000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1274513000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	127722000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	117484000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	382339000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298673000	USD
CY2020Q3	pcrx	Acquisition Related Gain Loss Product Discontinuation Costs And Other Net AcquisitionRelatedGainLossProductDiscontinuationCostsAndOtherNet	-692000	USD
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	34651000	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	29993000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	101248000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	82031000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11578000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14651000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40031000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44090000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48807000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52561000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	148142000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	140683000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1967000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1967000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5900000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5900000	USD
CY2021Q3	pcrx	Acquisition Related Gain Loss Product Discontinuation Costs And Other Net AcquisitionRelatedGainLossProductDiscontinuationCostsAndOtherNet	714000	USD
	pcrx	Acquisition Related Gain Loss Product Discontinuation Costs And Other Net AcquisitionRelatedGainLossProductDiscontinuationCostsAndOtherNet	-1305000	USD
	pcrx	Acquisition Related Gain Loss Product Discontinuation Costs And Other Net AcquisitionRelatedGainLossProductDiscontinuationCostsAndOtherNet	1599000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	96289000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	99864000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	296626000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	271105000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	31433000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	17620000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	85713000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	27568000	USD
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	177000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1025000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	816000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3936000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	7333000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	7132000	USD
	us-gaap	Interest Expense InterestExpense	21327000	USD
	us-gaap	Interest Expense InterestExpense	18609000	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8071000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8071000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-46000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2708000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2600000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2571000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7202000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11470000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23111000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20173000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	24231000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6150000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	62602000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7395000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6571000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-123969000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15492000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-123613000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	17660000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	130119000	USD
	us-gaap	Net Income Loss NetIncomeLoss	47110000	USD
	us-gaap	Net Income Loss NetIncomeLoss	131008000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.40
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.09
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.39
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.94
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.02
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44476000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42928000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44151000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42393000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45463000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44275000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45674000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43333000	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	17660000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	130119000	USD
	us-gaap	Net Income Loss NetIncomeLoss	47110000	USD
	us-gaap	Net Income Loss NetIncomeLoss	131008000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-30000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-643000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-168000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	525000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	3000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-28000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-643000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-165000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	525000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	17632000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	129476000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	46945000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	131533000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	687168000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3018000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10784000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-28000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	17660000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	718602000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	388148000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24582000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10954000	USD
CY2020Q3	us-gaap	Income Tax Effects Allocated Directly To Equity Equity Transactions IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions	20450000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-643000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	130119000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	584690000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	619688000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	19039000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1574000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31356000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-165000	USD
	us-gaap	Net Income Loss NetIncomeLoss	47110000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	718602000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	354944000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36238000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1421000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29024000	USD
	us-gaap	Income Tax Effects Allocated Directly To Equity Equity Transactions IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions	20450000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	525000	USD
	us-gaap	Net Income Loss NetIncomeLoss	131008000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	584690000	USD
	us-gaap	Net Income Loss NetIncomeLoss	47110000	USD
	us-gaap	Net Income Loss NetIncomeLoss	131008000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	12953000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-124572000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15478000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14847000	USD
	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	1976000	USD
	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	1512000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	17245000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	12684000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8071000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	10000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	31356000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29024000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2147000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1560000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2641000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-2779000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3070000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1386000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2560000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10246000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-907000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	382000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-825000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1117000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-17034000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-16454000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1996000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1670000	USD
	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	5662000	USD
	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	9409000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	102502000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	30365000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36700000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23393000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	513492000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	326664000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	470614000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	154767000	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	17187000	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	9057000	USD
	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87708000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-195290000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19049000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	35980000	USD
	pcrx	Proceeds From Shares Issued Under Employee Stock Purchase Plans ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans	1574000	USD
	pcrx	Proceeds From Shares Issued Under Employee Stock Purchase Plans ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlans	1421000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	12487000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1338000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	5591000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19285000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	211941000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34079000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	47016000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99957000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78228000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134036000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125244000	USD
	us-gaap	Interest Paid Net InterestPaidNet	5096000	USD
	us-gaap	Interest Paid Net InterestPaidNet	5305000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2259000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2329000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4719000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9442000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	35434000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	26886000	USD
CY2021Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	17222000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	16266000	USD
CY2021Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14553000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	21498000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	67209000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	64650000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	247045000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	215048000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	87810000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	78360000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	159235000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	136688000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	3800000	USD
	us-gaap	Depreciation Depreciation	9600000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	3100000	USD
	us-gaap	Depreciation Depreciation	8900000	USD
CY2021Q3	pcrx	Foreign Property Plant And Equipment Net ForeignPropertyPlantAndEquipmentNet	66900000	USD
CY2020Q4	pcrx	Foreign Property Plant And Equipment Net ForeignPropertyPlantAndEquipmentNet	67500000	USD
CY2021Q3	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2100000	USD
CY2020Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2000000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P8Y10M24D
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2919000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	3099000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	8762000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	7085000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	416000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	611000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	1318000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	1661000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	3335000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	3710000	USD
	us-gaap	Lease Cost LeaseCost	10080000	USD
	us-gaap	Lease Cost LeaseCost	8746000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	9868000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	11251000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	212000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	42101000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y5M15D
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y4M20D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0688
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0688
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2659000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10645000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10697000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10980000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11271000	USD
CY2021Q3	pcrx	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	50802000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	97054000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	24391000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	72663000	USD
	pcrx	Lessee Operating Lease Lease Not Yet Commenced Number Of Contracts LesseeOperatingLeaseLeaseNotYetCommencedNumberOfContracts	1	segment
CY2021Q3	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Remainder Of Fiscal Year LesseeOperatingLeaseLeaseNotYetCommencedLiabilityRemainderOfFiscalYear	0	USD
CY2021Q3	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year One LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearOne	439000	USD
CY2021Q3	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year Two LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearTwo	453000	USD
CY2021Q3	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year Three LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearThree	466000	USD
CY2021Q3	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year Four LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearFour	480000	USD
CY2021Q3	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due After Year Four LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueAfterYearFour	495000	USD
CY2021Q3	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability LesseeOperatingLeaseLeaseNotYetCommencedLiability	2333000	USD
CY2021Q3	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	99500000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	99500000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5900000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5900000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2000000	USD
CY2021Q3	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period1 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod1	7900000	USD
CY2021Q3	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period2 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod2	2200000	USD
	pcrx	Settlement Period Convertible Debt Conversion Request SettlementPeriodConvertibleDebtConversionRequest	P40D
	pcrx	Deferred Tax Expense Associated To The Equity Component Of Convertible Debt DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt	20500000	USD
	pcrx	Amortization Period Of Transaction Costs Attributable To Liability Component Of Convertible Debt AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt	P5Y
	pcrx	Transaction Costs Attributable To The Equity Component Of Convertible Debt TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt	2700000	USD
CY2021Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1704000	USD
CY2020Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1764000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	5122000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	5861000	USD
CY2021Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	666000	USD
CY2020Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	629000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1976000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1512000	USD
CY2021Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5844000	USD
CY2020Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5430000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	17245000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	12684000	USD
CY2021Q3	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	881000	USD
CY2020Q3	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	691000	USD
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	3016000	USD
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1448000	USD
CY2021Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	7333000	USD
CY2020Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	7132000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	21327000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	18609000	USD
CY2021Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0670
CY2020Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0678
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0670
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0735
CY2021Q3	us-gaap	Share Price SharePrice	56.00
	pcrx	Milestone Payment MilestonePayment	7000000	USD
CY2021Q3	pcrx	Milestone Payment MilestonePayment	5000000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	559723000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	109000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	559822000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	516845000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	350000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	31000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	517164000	USD
CY2021Q3	us-gaap	Interest Receivable InterestReceivable	400000	USD
CY2020Q4	us-gaap	Interest Receivable InterestReceivable	1600000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1500000	shares
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10784000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10954000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31356000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29024000	USD
CY2021Q3	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	6458000	USD
CY2020Q3	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	7181000	USD
	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	19507000	USD
	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	19795000	USD
CY2021Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	4126000	USD
CY2020Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	3552000	USD
	us-gaap	Restricted Stock Expense RestrictedStockExpense	11164000	USD
	us-gaap	Restricted Stock Expense RestrictedStockExpense	8589000	USD
CY2021Q3	pcrx	Compensation Expense From Employee Stock Purchase Plan CompensationExpenseFromEmployeeStockPurchasePlan	200000	USD
CY2020Q3	pcrx	Compensation Expense From Employee Stock Purchase Plan CompensationExpenseFromEmployeeStockPurchasePlan	221000	USD
	pcrx	Compensation Expense From Employee Stock Purchase Plan CompensationExpenseFromEmployeeStockPurchasePlan	685000	USD
	pcrx	Compensation Expense From Employee Stock Purchase Plan CompensationExpenseFromEmployeeStockPurchasePlan	640000	USD
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	10784000	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	10954000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	31356000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29024000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6235118	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	45.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	769352	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	61.33
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	553023	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	34.43
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	238865	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	46.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	42416	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	76.62
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6170166	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	48.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	27.36
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.85
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	31230	shares
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	54000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	17660000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	130119000	USD
	us-gaap	Net Income Loss NetIncomeLoss	47110000	USD
	us-gaap	Net Income Loss NetIncomeLoss	131008000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44476000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42928000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44151000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42393000	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	51000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45463000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44275000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45674000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43333000	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.40
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.09
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.39
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.94
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.02
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3102000	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3615000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2036000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4894000	shares
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	25167000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	8175000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	66962000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	10154000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-936000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2025000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4360000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2759000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	24231000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6150000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	62602000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7395000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6600000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-124000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15500000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-123600000	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-124600000	USD
CY2020Q3	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-124600000	USD

Files In Submission

Name	View Source	Status
0001396814-21-000063-index-headers.html	Edgar Link	pending
0001396814-21-000063-index.html	Edgar Link	pending
0001396814-21-000063.txt	Edgar Link	pending
0001396814-21-000063-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pcrx-20210930.htm	Edgar Link	pending
pcrx-20210930.xsd	Edgar Link	pending
pcrx-20210930_cal.xml	Edgar Link	unprocessable
pcrx-20210930_def.xml	Edgar Link	unprocessable
pcrx-20210930_g1.jpg	Edgar Link	pending
pcrx-20210930_g2.jpg	Edgar Link	pending
pcrx-20210930_htm.xml	Edgar Link	completed
pcrx-20210930_lab.xml	Edgar Link	unprocessable
pcrx-20210930_pre.xml	Edgar Link	unprocessable
pcrx-9302021xex311.htm	Edgar Link	pending
pcrx-9302021xex312.htm	Edgar Link	pending
pcrx-9302021xex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira Biosciences Inc Stock $pcrx

2021 Q4 Form 10-Q Financial Statement

#000139681421000063 Filed on November 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira Biosciences Inc Stock $pcrx

2021 Q4 Form 10-Q Financial Statement

#000139681421000063 Filed on November 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira Biosciences Inc Stock $pcrx